PT - JOURNAL ARTICLE AU - Robertson, McKaylee M AU - Qasmieh, Saba A AU - Kulkarni, Sarah G AU - Teasdale, Chloe A AU - Jones, Heidi AU - McNairy, Margaret AU - Borrell, Luisa N. AU - Nash, Denis TI - The epidemiology of long COVID in US adults two years after the start of the US SARS-CoV-2 pandemic AID - 10.1101/2022.09.12.22279862 DP - 2022 Jan 01 TA - medRxiv PG - 2022.09.12.22279862 4099 - http://medrxiv.org/content/early/2022/09/14/2022.09.12.22279862.short 4100 - http://medrxiv.org/content/early/2022/09/14/2022.09.12.22279862.full AB - Objectives To characterize prevalence and impact of long COVID.Methods We conducted a population-representative survey, June 30-July 2, 2022, of a random sample of 3,042 United States adults. Using questions developed by the United Kingdom’s Office of National Statistics, we estimated the prevalence by sociodemographics, adjusting for gender and age.Results An estimated 7.3% (95% CI: 6.1-8.5%) of all respondents reported long COVID, approximately 18,533,864 adults. One-quarter (25.3% [18.2-32.4%]) of respondents with long COVID reported their day-to-day activities were impacted ‘a lot’ and 28.9% had SARS-CoV-2 infection >12 months ago. The prevalence of long COVID was higher among respondents who were female (aPR: 1.84 [1.40-2.42]), had comorbidities (aPR: 1.55 [1.19-2.00]) or were not (versus were) boosted (aPR: 1.67 [1.19-2.34]) or not vaccinated (versus boosted) (aPR: 1.41 (1.05-1.91)).Conclusions We observed a high burden of long COVID and substantial variability in prevalence of SARS-CoV-2. Population-based surveys are an important surveillance tool and supplement to ongoing efforts to monitor long COVID.Competing Interest StatementMMR, DN and SGK receive support from PfizerFunding StatementFunding for this project was provided by the CUNY Institute for Implementation Science in Population Health (cunyisph.org).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Institutional Review Board at the City University of New York (CUNY IRB 2022-0407).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors